The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
The Association Between Tirzepatide Versus Insulin Glargine and NT-proBNP Levels in People With Type 2 Diabetes With or at Elevated Risk for Cardiovascular Disease: Post hoc Analyses of SURPASS 4
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Previous studies in people with obesity-associated heart failure with preserved ejection fraction showed greater improvements in 6-minute walk distance and quality of life measures and preliminary evidence of a reduction in cardiovascular events, though these studies were small and relatively short in duration.
“This has been evidenced by demonstrating greater improvements in 6-minute walk distance and quality of life measures and preliminary evidence of a reduction in CV events in these studies, which were small and relatively short in duration.”
From Outcomes in patients with diabetes, atherosclerotic cardiovascular disease, and heart failure treated with tirzepatide or dulaglutide: SURPASS-CVOT analysis (2026) · cites this paper as [15]
Split into 2 atoms — 0 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 1 unverifiable. Expand the claim to see per-atom verdicts.
Experimental — accuracy not yet measuredPrevious studies have demonstrated favourable effects of semaglutide and tirzepatide in people with obesity-associated heart failure with preserved ejection fraction.
“Previous studies have demonstrated favourable effects of both the GLP-1 receptor agonist, semaglutide, and the GIP/GLP-1 receptor agonist, tirzepatide, in people with obesity associated HFpEF.6,[13][14][15]”
From Outcomes in patients with diabetes, atherosclerotic cardiovascular disease, and heart failure treated with tirzepatide or dulaglutide: SURPASS-CVOT analysis (2026) · cites this paper as [15]
These findings were present in patients with or without type 2 diabetes.
“These findings were present in patients with or without T2D.14,15”
From Outcomes in patients with diabetes, atherosclerotic cardiovascular disease, and heart failure treated with tirzepatide or dulaglutide: SURPASS-CVOT analysis (2026) · cites this paper as [15]
The greater weight loss achieved with tirzepatide versus dulaglutide in this trial may be relevant to the quality-of-life findings, given that greater weight loss has been associated with greater KCCQ benefits in prior studies of incretins in patients with heart failure with preserved ejection fraction.
“The greater weight loss achieved with tirzepatide vs. dulaglutide in this trial may be relevant to these findings, given that greater weight loss has been associated with greater KCCQ benefits in prior studies of incretins in patients living with HFpEF.[13][14][15]”
From Outcomes in patients with diabetes, atherosclerotic cardiovascular disease, and heart failure treated with tirzepatide or dulaglutide: SURPASS-CVOT analysis (2026) · cites this paper as [15]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity
Kosiborod, M. N., Abildstrøm, S. Z., Borlaug, B. A., Butler, J., Rasmussen, S., Davies, M., Hovingh, G. K., Kitzman, D. W., Lindegaard, M. L., Møller, D. V., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2306963 · Cited by 1,669
Self-citationTirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity
Packer, M., Zile, M. R., Kramer, C. M., Baum, S. J., Litwin, S. E., Menon, V., Ge, J., Weerakkody, G. J., Ou, Y., Bunck, M. C., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2410027 · Cited by 1,009
Self-citationCardiac natriuretic peptides in plasma increase after dietary induced weight loss in obesity
Kistorp, C., Bliddal, H., Goetze, J. P., Christensen, R., & Faber, J. (2014) · BMC Obesity · doi:10.1186/s40608-014-0024-2 · Cited by 31
Flagged first, then by citations
Research works printed but not linked: 2
- 10.1056/NEJMoa2313917 · DOI · Paper page
- 10.1016/S0140-6736(21)02188-7 · DOI · Paper page
Cited by
Sorted by citations
Ndumele, C. E., Rodriguez, F., Dixon, D. L., Khan, S. S., Mukherjee, D., Bajaj, M., Bangalore, S., Bozkurt, B., Breathett, K., Clarke, S. L., et al. (2026) · JACC · doi:10.1016/j.jacc.2026.03.056 · Cited by 90
Nicholls, S. J., Pavo, I., Bhatt, D. L., Buse, J. B., Del Prato, S., Franco, D. R., Kahn, S. E., Lincoff, A. M., Martins, R. F., McGuire, D. K., et al. (2026) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwag452
Self-citation
Metadata
- Authors
- Sattar, N., Weerakkody, G. J., McGuire, D. K., Kosiborod, M. N., Lee, M. M. Y., Welsh, P., Pearson, E. R., Wiese, R. J., Duffin, K., Wilson, J., Pavo, N., Hülsmann, M., & Pavo, I.
- Affiliations
- School of Cardiovascular and Metabolic Health, Glasgow Cardiovascular Research Centre, University of Glasgow, UK (N.S., M.M.Y.L., P.W.).
- Eli Lilly and Company, Indianapolis, IN (G.J.W., R.J.W., K.D., J.W., I.P.).
- Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas (D.K.M.).
- Saint Luke’s Hospital of Kansas City, Kansas (M.N.K.).
- Division of Population Health and Genomics, Ninewells Hospital and School of Medicine, University of Dundee, UK (E.R.P.).
- Department of Internal Medicine II, Division of Cardiology, Medical University of Vienna, Austria (N.P., M.H.).
- ORCID
- Venue
- Circulation
- Published
- 2025-05-13
- Volume
- 151
- Issue
- 19
- Pages
- 1430-1432
- ISSN
- 0009-7322
- 1524-4539
- Cited by
- 6
- References
- 3
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
